Correlation Between Y MAbs and Travere Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Y MAbs and Travere Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Y MAbs and Travere Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Y mAbs Therapeutics and Travere Therapeutics, you can compare the effects of market volatilities on Y MAbs and Travere Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Y MAbs with a short position of Travere Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Y MAbs and Travere Therapeutics.

Diversification Opportunities for Y MAbs and Travere Therapeutics

-0.24
  Correlation Coefficient

Very good diversification

The 3 months correlation between YMAB and Travere is -0.24. Overlapping area represents the amount of risk that can be diversified away by holding Y mAbs Therapeutics and Travere Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Travere Therapeutics and Y MAbs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Y mAbs Therapeutics are associated (or correlated) with Travere Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Travere Therapeutics has no effect on the direction of Y MAbs i.e., Y MAbs and Travere Therapeutics go up and down completely randomly.

Pair Corralation between Y MAbs and Travere Therapeutics

Given the investment horizon of 90 days Y mAbs Therapeutics is expected to generate 1.14 times more return on investment than Travere Therapeutics. However, Y MAbs is 1.14 times more volatile than Travere Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Travere Therapeutics is currently generating about 0.02 per unit of risk. If you would invest  459.00  in Y mAbs Therapeutics on September 13, 2024 and sell it today you would earn a total of  542.00  from holding Y mAbs Therapeutics or generate 118.08% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Y mAbs Therapeutics  vs.  Travere Therapeutics

 Performance 
       Timeline  
Y mAbs Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Y mAbs Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Travere Therapeutics 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Travere Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Travere Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Y MAbs and Travere Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Y MAbs and Travere Therapeutics

The main advantage of trading using opposite Y MAbs and Travere Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Y MAbs position performs unexpectedly, Travere Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Travere Therapeutics will offset losses from the drop in Travere Therapeutics' long position.
The idea behind Y mAbs Therapeutics and Travere Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Complementary Tools

USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities